• Explore /
  • Poster
  • / Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).

Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Karim Boudadi

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Karim Boudadi , Daniel L. Suzman , Brandon Luber , Hao Wang , John Silberstein , Rana Sullivan , Donna Dowling , Rana Harb , Thomas Nirschl , Ryan Vance Dittamore , Michael Anthony Carducci , Mario A. Eisenberger , Michael Haffner , Alan Meeker , James R. Eshleman , Jun Luo , Charles G. Drake , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02601014

Citation

J Clin Oncol 35, 2017 (suppl; abstr 5035)

DOI

10.1200/JCO.2017.35.15_suppl.5035

Abstract #

5035

Poster Bd #

109

Abstract Disclosures

Similar Posters

First Author: Rahul Raj Aggarwal

First Author: Xiao X. Wei

First Author: Kamal Kant Kant Sahu

First Author: Justin Shaya